The obligation of AMFIL to ensure successful execution of this Agreement is as follows: a) AMFIL will have negotiated in good faith consistent with the terms and conditions set out in this JVA. AMFIL is satisfied, in its sole discretion, that the present operational and financial status of A.C.T.S. Inc. is in a transitional stage and that A.C.T.S. Inc. is positioning its company to re-launch its operational status to accommodate the Development, Integration, Application of the mPact - GROzone Antimicrobial Systems as per description in the above mentioned “Purpose” b) AMFIL will be satisfied, in its sole discretion, with its Due Diligence Review c) AMFIL will be satisfied, in its sole discretion, that the Representation Rights, save as stated in (b) above and as stated in this Agreement, are not encumbered in any manner and A.C.T.S. Inc. has not granted any rights as per description in the above mentioned “Purpose” to any other parties; and d) AMFIL will be responsible for all payments to the AMFE-ACTS JV as per Clause 10 “Capital Contributions”, and Clause 11 “Contribution Schedule Description”. e) The parties will have received all regulatory consents and approvals required in connection with the transaction set out herein including obtaining approval of the Securities and Exchange Commission (SEC) to list and post for trading the AMFIL Shares issuable to A.C.T.S. Inc. and aforementioned associates. |